Literature DB >> 26354981

A geographical cluster of progressive supranuclear palsy in northern France.

Dominique Caparros-Lefebvre1, Lawrence I Golbe2, Vincent Deramecourt2, Claude-Alain Maurage2, Vincent Huin2, Valerie Buée-Scherrer2, Helene Obriot2, Bernard Sablonnière2, Francois Caparros2, Luc Buée2, Andrew J Lees2.   

Abstract

OBJECTIVE: To describe a cluster of progressive supranuclear palsy (PSP) in northern France. PSP has not been reported in geographical, temporal, or occupational clusters. A unit of Neurology and Neurogeriatrics opened in 2005 at the Centre Hospitalier de Wattrelos, serving the population of Wattrelos and Leers (combined population 51,551) and parts of neighboring towns. For most of the 20th century, this area was a center for chromate and phosphate ore processing, textile dyeing, and tanning. Significant industrial waste persists close to residential areas.
METHODS: From 2005 to 2014, 92 patients with PSP at Centre Hospitalier de Wattrelos were identified and studied. Detailed residential data were available in the medical records. Eighty cases have had magnetic resonance head scanning and 60 have died, of whom 13 have been examined neuropathologically.
RESULTS: The ratio of observed to expected PSP incidence over the period 2005 to 2012 was 12.3 (95% confidence interval: 7.4-35.9). Mean onset age was 74.3 years. The Richardson syndrome/PSP-parkinsonism ratio was 43%/42%. Four other phenotypes each occurred in 2% to 5%. Onset was gait/balance difficulty in 52%. None of the 92 affected patients were relatives and 7 were of North African ancestry. MRI was compatible with a clinical diagnostic of PSP in all cases. Histopathologic examination confirmed neurofibrillary degeneration and tufted astrocytes in all autopsied cases. Western blots revealed a typical tau 4R doublet. The tau H1 haplotype occurred in 95.8% of cases' chromosomes.
CONCLUSIONS: We have identified a cluster of PSP in a geographical area with severe environmental contamination by industrial metals.
© 2015 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26354981      PMCID: PMC4617163          DOI: 10.1212/WNL.0000000000001997

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  34 in total

1.  The epidemiology of progressive supranuclear palsy.

Authors:  Lawrence I Golbe
Journal:  Handb Clin Neurol       Date:  2008

2.  Tau pathology involves protein phosphatase 2A in parkinsonism-dementia of Guam.

Authors:  Mohammad Arif; Syed Faraz Kazim; Inge Grundke-Iqbal; Ralph M Garruto; Khalid Iqbal
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-06       Impact factor: 11.205

3.  Characterization of tau pathologies in gray and white matter of Guam parkinsonism-dementia complex.

Authors:  Matthew J Winton; Sonali Joyce; Victoria Zhukareva; Domenico Practico; Daniel P Perl; Douglas Galasko; Ula Craig; John Q Trojanowski; Virginia M-Y Lee
Journal:  Acta Neuropathol       Date:  2006-04-12       Impact factor: 17.088

4.  Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy.

Authors:  Günter U Höglinger; Nadine M Melhem; Dennis W Dickson; Patrick M A Sleiman; Li-San Wang; Lambertus Klei; Rosa Rademakers; Rohan de Silva; Irene Litvan; David E Riley; John C van Swieten; Peter Heutink; Zbigniew K Wszolek; Ryan J Uitti; Jana Vandrovcova; Howard I Hurtig; Rachel G Gross; Walter Maetzler; Stefano Goldwurm; Eduardo Tolosa; Barbara Borroni; Pau Pastor; Laura B Cantwell; Mi Ryung Han; Allissa Dillman; Marcel P van der Brug; J Raphael Gibbs; Mark R Cookson; Dena G Hernandez; Andrew B Singleton; Matthew J Farrer; Chang-En Yu; Lawrence I Golbe; Tamas Revesz; John Hardy; Andrew J Lees; Bernie Devlin; Hakon Hakonarson; Ulrich Müller; Gerard D Schellenberg
Journal:  Nat Genet       Date:  2011-06-19       Impact factor: 38.330

5.  Risk factors for progressive supranuclear palsy: a case-control study in France.

Authors:  J-S Vidal; M Vidailhet; P Derkinderen; T Dubard de Gaillarbois; C Tzourio; A Alpérovitch
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-11       Impact factor: 10.154

6.  Arsenic, cadmium and lead in medicinal herbs and their fractionation.

Authors:  S Arpadjan; G Celik; S Taşkesen; S Güçer
Journal:  Food Chem Toxicol       Date:  2008-06-03       Impact factor: 6.023

7.  Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC).

Authors:  Judith Miklossy; John C Steele; Sheng Yu; Sherman McCall; Glenn Sandberg; Edith G McGeer; Patrick L McGeer
Journal:  Acta Neuropathol       Date:  2008-10-09       Impact factor: 17.088

8.  Natural lipophilic inhibitors of mitochondrial complex I are candidate toxins for sporadic neurodegenerative tau pathologies.

Authors:  Matthias Höllerhage; Andreas Matusch; Pierre Champy; Anne Lombès; Merle Ruberg; Wolfgang H Oertel; Günter U Höglinger
Journal:  Exp Neurol       Date:  2009-08-13       Impact factor: 5.330

9.  Similarities between familial and sporadic autopsy-proven progressive supranuclear palsy.

Authors:  Shinsuke Fujioka; Avi A Algom; Melissa E Murray; Audrey Strongosky; Alexandra I Soto-Ortolaza; Rosa Rademakers; Owen A Ross; Zbigniew K Wszolek; Dennis W Dickson
Journal:  Neurology       Date:  2013-05-01       Impact factor: 9.910

10.  The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts.

Authors:  Amanda J Myers; Alan M Pittman; Alice S Zhao; Kristen Rohrer; Mona Kaleem; Lauren Marlowe; Andrew Lees; Doris Leung; Ian G McKeith; Robert H Perry; Chris M Morris; John Q Trojanowski; Christopher Clark; Jason Karlawish; Steve Arnold; Mark S Forman; Vivianna Van Deerlin; Rohan de Silva; John Hardy
Journal:  Neurobiol Dis       Date:  2006-12-15       Impact factor: 5.996

View more
  10 in total

Review 1.  Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.

Authors:  Adam L Boxer; Jin-Tai Yu; Lawrence I Golbe; Irene Litvan; Anthony E Lang; Günter U Höglinger
Journal:  Lancet Neurol       Date:  2017-06-13       Impact factor: 44.182

2.  Tauopathy-associated PERK alleles are functional hypomorphs that increase neuronal vulnerability to ER stress.

Authors:  Shauna H Yuan; Nobuhiko Hiramatsu; Qing Liu; Xuehan Victoria Sun; David Lenh; Priscilla Chan; Karen Chiang; Edward H Koo; Aimee W Kao; Irene Litvan; Jonathan H Lin
Journal:  Hum Mol Genet       Date:  2018-11-15       Impact factor: 6.150

3.  Progressive Supranuclear Palsy and Corticobasal Degeneration.

Authors:  David G Coughlin; Dennis W Dickson; Keith A Josephs; Irene Litvan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study.

Authors:  Irene Litvan; Peter S J Lees; Christopher R Cunningham; Shesh N Rai; Alexander C Cambon; David G Standaert; Connie Marras; Jorge Juncos; David Riley; Stephen Reich; Deborah Hall; Benzi Kluger; Yvette Bordelon; David R Shprecher
Journal:  Mov Disord       Date:  2016-02-08       Impact factor: 10.338

Review 5.  Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies.

Authors:  Maria Stamelou; Gesine Respondek; Nikolaos Giagkou; Jennifer L Whitwell; Gabor G Kovacs; Günter U Höglinger
Journal:  Nat Rev Neurol       Date:  2021-08-23       Impact factor: 42.937

6.  Traumatic Brain Injury and Firearm Use and Risk of Progressive Supranuclear Palsy Among Veterans.

Authors:  Kristen D Kelley; Harvey Checkoway; Deborah A Hall; Stephen G Reich; Chris Cunningham; Irene Litvan
Journal:  Front Neurol       Date:  2018-06-20       Impact factor: 4.003

7.  Hypothesis: Etiologic and Molecular Mechanistic Leads for Sporadic Neurodegenerative Diseases Based on Experience With Western Pacific ALS/PDC.

Authors:  Peter S Spencer
Journal:  Front Neurol       Date:  2019-07-31       Impact factor: 4.003

Review 8.  Frontrunner in Translation: Progressive Supranuclear Palsy.

Authors:  Ali Shoeibi; Nahid Olfati; Irene Litvan
Journal:  Front Neurol       Date:  2019-10-22       Impact factor: 4.003

Review 9.  Chinese nutraceuticals and physical activity; their role in neurodegenerative tauopathies.

Authors:  Abdullahi Alausa; Sunday Ogundepo; Barakat Olaleke; Rofiat Adeyemi; Mercy Olatinwo; Aminat Ismail
Journal:  Chin Med       Date:  2021-01-06       Impact factor: 5.455

Review 10.  Cellular and pathological heterogeneity of primary tauopathies.

Authors:  Dah-Eun Chloe Chung; Shanu Roemer; Leonard Petrucelli; Dennis W Dickson
Journal:  Mol Neurodegener       Date:  2021-08-23       Impact factor: 18.879

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.